Replies to post #213674 on Biotech Values

[biomaven0]

>>BMY withdraws Opdivo MAA in second-line HCC

That's surprising - I thought the data looked pretty good.

If I recall correctly, they have a US PDUFA date later this month for this indication.

[DewDiligence]

BMY’s CHECKMATE-459 study testing Opdivo-vs-Nexavar in 1L-HCC fails to show statsig OS advantage (HR=0.85; 95% CI=[0.72, 1.02]; p=0.075):

https://finance.yahoo.com/news/bristol-myers-squibb-announces-results-105900314.html

This was a fairly close miss.